Search for content, post, videos

Biohit co-operates with Tianjin Jingsheng Biological Technology Development Co

agreement

Biohit Oyj and Tianjin Jingsheng Biological Technology Development Co Ltd have signed a distributor agreement for the distribution of the Biohit Calprotectin ELISA test in China.

Biohit Calprotectin test is a useful quick test for measuring calprotectin in a stool sample. The test is used to differentiate inflammatory bowel disease (IBD) from irritable bowel syndrome (IBS) as well as in monitoring of the treatment in IBD patients. Inflammatory bowel diseases are Crohn’s disease and ulcerative colitis, diagnosed increasingly. Particularly ulcerative colitis is linked with an increased risk of colon cancer.

The test measures calprotectin released from the inflamed intestinal mucosa into faeces. Calprotectin is derived from the inflammatory cells, and its concentration in the faeces reflects the activity of the inflammation and the efficacy of the treatment in IBD patients. In patients with IBS, this test is usually negative.

General Director Zeng Zhao Hong, Tianjin Jingsheng Biological Technology Development Co. Ltd.:  ‘In China there seems to be differences in prevalence of IBD between rural and urban population. The disease is increasing particularly among young people. Fecal calprotectin is an emerging biomarker of gut inflammation. Biohit Calprotectin test differentiates reliably IBD and IBS and reduces significantly the need of colonoscopies.’

CEO Semi Korpela, Biohit Oyj: ‘We are starting a co-operation with Tianjin Jingsheng Biological Technology Development Co. Ltd in the large Chinese market. We have started the registration in China required to obtain the marketing authorisation for the product.’
Source: Healthtech Finland